Opus Genetics highlights 2025 progress, 2026 catalysts

Opus Genetics, Inc. furnished a current report to share a new corporate update with investors.

Rhea-AI Filing Summary

Opus Genetics, Inc. furnished a current report to share a new corporate update with investors. The company submitted an 8-K that includes a press release titled “Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts,” indicating it has summarized recent achievements from 2025 and outlined important expected milestones for 2026. The information is provided under a disclosure item that is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Opus Genetics (IRD) report in this 8-K filing?

Opus Genetics furnished an 8-K to provide investors with a press release titled “Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts,” summarizing recent progress and expected 2026 milestones.

What is the main purpose of Opus Genetics’ January 8, 2026 update?

The company’s update is to highlight its 2025 progress and describe upcoming 2026 catalysts, as set out in the press release attached as Exhibit 99.1 to the 8-K.

Is the Opus Genetics 8-K information considered filed or furnished?

The 8-K states that the information in Item 7.01, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act, nor automatically incorporated by reference into other filings.

What exhibit is included with Opus Genetics’ January 8, 2026 8-K?

The filing includes Exhibit 99.1, a press release dated January 8, 2026, and Exhibit 104.1, the cover page interactive data file embedded in the Inline XBRL document.

Who signed the Opus Genetics January 8, 2026 8-K?

The 8-K was signed on behalf of Opus Genetics, Inc. by Dr. George Magrath, the company’s Chief Executive Officer.

Does the Opus Genetics 8-K describe specific financial results?

The 8-K itself does not describe specific financial metrics; it notes a press release that highlights 2025 progress and upcoming 2026 catalysts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 07:10 AM Learn about SEC filing dates

false000122862700012286272026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

Opus Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-34079	11-3516358
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8 Davis Drive Durham, NC		27713
(Address of principal executive offices)		(Zip Code)

(984) 884-6030

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	IRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 8, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release entitled “Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts.” A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated January 8, 2026.
104.1	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OPUS GENETICS, INC.
Date: January 8, 2026	By:	/s/ Dr. George Magrath
	Name:	Dr. George Magrath
	Title:	Chief Executive Officer